Lighthouse Investment Partners LLC Makes New $1.04 Million Investment in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Lighthouse Investment Partners LLC acquired a new position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRSFree Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 313,134 shares of the biotechnology company’s stock, valued at approximately $1,043,000.

Other institutional investors also recently bought and sold shares of the company. RPO LLC purchased a new position in shares of Coherus BioSciences in the 4th quarter valued at $65,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Coherus BioSciences in the 4th quarter valued at $81,000. TrinityPoint Wealth LLC purchased a new position in shares of Coherus BioSciences in the 4th quarter valued at $40,000. Baader Bank Aktiengesellschaft purchased a new position in Coherus BioSciences during the 4th quarter worth $47,000. Finally, Jump Financial LLC grew its stake in Coherus BioSciences by 50.6% during the 4th quarter. Jump Financial LLC now owns 33,267 shares of the biotechnology company’s stock worth $111,000 after buying an additional 11,180 shares during the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Coherus BioSciences Stock Performance

Shares of Coherus BioSciences stock opened at $1.74 on Tuesday. Coherus BioSciences, Inc. has a twelve month low of $1.43 and a twelve month high of $5.63. The business has a 50-day moving average price of $2.09 and a 200 day moving average price of $2.30.

Coherus BioSciences (NASDAQ:CHRSGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The company had revenue of $77.06 million during the quarter, compared to analysts’ expectations of $102.00 million. During the same period in the previous year, the company posted ($0.89) EPS. As a group, equities analysts expect that Coherus BioSciences, Inc. will post -1.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on CHRS shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Coherus BioSciences in a research report on Friday, May 24th. Truist Financial lowered their price target on Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, May 13th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from, Coherus BioSciences has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Check Out Our Latest Report on CHRS

Coherus BioSciences Company Profile

(Free Report)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

See Also

Want to see what other hedge funds are holding CHRS? Visit to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. (NASDAQ:CHRSFree Report).

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with's FREE daily email newsletter.